Inovio Pharmaceuticals Inc., of Blue Bell, Pa., published positive preclinical results for its Chikungunya virus vaccine in PloS Neglected Tropical Diseases. The vaccine protected mice against the virus and induced neutralizing antibodies in mice and nonhuman primates.